2192281-54-0
Chemical Structure
Zadavotide guraxetan
Synonym(s): PSMA I&T; PNT-2002
- CAS No.: 2192281-54-0
- Formula:C63H92IN11O23
- Molecular Weight:1498.37
IUPAC Name: (2S,3S,4S,5R,6R)-6-(((2R,3R,4S,5S,6S)-2-(((3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl)oxy)-4,5-dihydroxy-6-(methoxycarbonyl)tetrahydro-2H-pyran-3-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid
InChIKey: HPLNQICCRXHOIA-IEHTVPKNSA-N
SMILES: IC(C=C1C[C@H](C(N[C@@H](C(N[C@@H](C(O)=O)CCCCNC(CCCCCCC(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)=O)=O)CC2=CC=CC=C2)=O)NC(CCC(N3CCN(CCN(CCN(CC3)CC(O)=O)CC(O)=O)CC(O)=O)C(O)=O)=O)=C(C=C1)O
Biological Activity: Zadavotide guraxetan (PSMA I&T; PNT-2002) is an effective inhibitor of prostate-specific membrane antigen (PSMA). Zadavotide guraxetan can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zadavotide guraxetan | 99.87% | Zadavotide guraxetan (PSMA I&T; PNT-2002) is an effective inhibitor of prostate-specific membrane antigen (PSMA). Zadavotide guraxetan can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Chatalic KL, et al. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. Theranostics. 2016 Apr 12;6(6):849-61. [Content Brief]
- [2]. Amelie Heesch, et al. The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [177Lu]Lu-PSMA-I&T for triple-negative breast cancer. Breast Cancer Res. 2024 Feb 20;26(1):30. [Content Brief]
